L

Lord Patel (CB)

Speaking in the House of Lords on 9 November 2026

Debate

Health Bill

Contribution

My Lords, I have put my name to several of these amendments. Much has been said already, so I will try to be brief. I will focus on two or three main things. One is where the developments are likely to lead us, which will complicate the issues even more than what we are talking about today. Let me come to cancer outcomes first. It has rightly been pointed out where England stands internationally in terms of cancer outcomes. Cancer outcomes are the ultimate truth: the truth in terms of one-year and five-year survival rates of any cancer. They are often what we use for international comparisons, but there is a system-wide reflection to be had. Poor survival outcomes are, often, a failure of several other processes, including when the diagnosis was made, the aggressive nature of the tumour—the later it is identified, the more aggressive it is likely to be—and whether the treatment was given at the right time. As was mentioned, delayed treatment increases the risk of mortality. Although the outcome, survival-wise, is an important parameter, there are other issues that need to be considered when assessing cancer outcomes, and they often relate to the processes. The balance metrics of measuring cancer outcomes may well include process indicators; operational timelines, in terms of how many days’ treatment the patient has; patient-centred outcomes, which are not often mentioned; and risk-adjusted clinical outcomes, based on the nature of the cancer. The core outcomes that are reported should include not only survival rates, but mortality rates, stage of diagnosis and operational and access metrics. The purpose of reporting—that is the important part for commissioning issues—is that accountability be taken into consideration. It should hold regional health services and Governments responsible for funding allocations and clinical performance, highlighting the gaps, and guiding policies and clinical improvements. Unless we have these measurements of outcomes, measuring survival rates only will not be enough. I will briefly mention genomics and radiotherapy. On radiotherapy, I get a daily, or sometimes weekly, bulletin from a medical oncology consultant whom I know extremely well; I will not name her. The important point has already been mentioned: it is not that we do not have the expertise in clinical capabilities, as Cancer Research UK has mentioned in its report; it is that bottlenecks occur in the processes afterwards. The surgery might be good, but there are bottlenecks in other forms of treatment. On radiotherapy, we have already mentioned the unmet needs, waiting times, regional disparities and workforce and equipment pressures. They will multiply with the advances that are coming in radiotherapy, which not all centres in England have implemented. It is good that NHS England announced a major rollout of stereotactic ablative radiotherapy, which reduced treatments for prostate cancers, for instance, from 20 to five. However, only a few centres now use advanced technology and AI together to further assist the planning of radiotherapy treatments, which can sometimes take days. There are developments occurring in radiotherapy that will put further pressures on patient access. With FLASH radiotherapy, for instance, radiotherapy is given in a concentrated way in a millisecond—not minutes, not hours, not days, but in a millisecond. Through biologically guided radiotherapy, integrated PET scanners, mentioned by the noble Baroness, Lady Finlay, are combined with linear accelerator scanners. They can immediately diagnose the nature of the cancer and deliver the appropriate therapy on the spot. Through generative AI adoption, AI is used while the patient is on the treatment table to identify the nature of the tumour and whether it can take higher-dose radiotherapy. There is also radiogenomics, whereby personalised genomics are associated with the behaviour of the tissue and the machine can decide whether it can give a higher dosage at a concentrated level. All these developments will put further pressure on our capacity to deliver to cancer patients, which needs to be addressed. There are lots of issues to be addressed but, finally and briefly, the Science and Technology Committee is about to produce a report on AI, genomics and personalised medicine, which identifies the role of genomics not only in cancer but in other areas too. Cancer, in particular, will require the rapid genomic analysis that the noble Baroness, Lady Finlay, mentioned. It is good that NHS England established seven genetic hubs that now do mutation screening and genomic screening, looking at the mutations in each and every cancer to see whether it will react to a particular treatment or not. They are building up a library, and it is important to continue building that library. Importantly, the only way to develop personalised medicine vaccines for delivery to individual patients is to do the genomics mutation study as rapidly as we can. The cancer genomics 10-year plan has identified all the issues, but it has not identified a way forward for implementation. This debate has emphasised that we need to know how we are going to deal with all the developments, deliver the cancer treatments and improve outcomes globally.

More from Lord Patel (CB)

Other recent Hansard contributions by the same speaker.

About Hansard

Hansard is the official verbatim record of proceedings in the UK Parliament. Every word spoken in the Commons and Lords is recorded and published — this page is a single contribution from that record.